Looking for a new broker?
Aptevo Therapeutics Inc. stock is down -17.83% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 December’s closed higher than November.
Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
